Hologic (HOLX)
(Delayed Data from NSDQ)
$75.98 USD
+0.27 (0.36%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $75.98 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth D Momentum D VGM
Price, Consensus and EPS Surprise
HOLX 75.98 +0.27(0.36%)
Will HOLX be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for HOLX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for HOLX
3 Medical Products Stocks Set to Beat This Earnings Season
Hologic (HOLX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
HOLX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
Hologic (HOLX) Stock Drops Despite Market Gains: Important Facts to Note
Other News for HOLX
Goldman’s buybacks basket: Buyback growth will be 13% in 2024
Agree To Purchase Hologic At $55, Earn 1.6% Annualized Using Options
ClearBridge Appreciation ESG Strategy Q1 2024 Portfolio Manager Commentary
ClearBridge Sustainability Leaders Strategy Q1 2024 Portfolio Manager Commentary
Hologic Inc. stock underperforms Tuesday when compared to competitors